The administration of l-thyroxine as soft gel capsule or liquid solution
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Levothyroxine (l-T4) is the mainstay of treating hypothyroidism. The tablet is the traditional formulation of l-T4. Tablet l-T4 malabsorption results from either hindered gastric dissolution of the tablet or binding of l-T4 by sequestrants in the intestinal lumen. AREAS COVERED: This review provides an overview of the pharmacokinetics of l-T4 formulations available in the market: the tablet, the soft gel capsule and the oral solution. We review literature on the new formulations and anticipate the areas of future research. EXPERT OPINION: Failure of l-T4 treatment to reach target serum thyroid-stimulating hormone levels generally prompts the physicians to increase l-T4 daily dose. In vitro studies have shown that the soft gel capsule releases the active ingredient more consistently at varying pH than the tablet. In addition, in vivo studies have confirmed the in vitro data and have demonstrated that both the soft gel capsule and the liquid formulation are capable to solve tablet l-T4 malabsorption caused by certain drugs, bariatric surgery or coffee. These new formulations may be attractive also for patients who cannot/do not want to change their (improper) habits of l-T4 ingestion. Finally, the oral solution l-T4 could be suitable for patients who cannot swallow the solid formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707 · cited 2×
“L-T4 is used at TSH-suppressive doses also to treat patients with nodular goiter, in order to slow/arrest its growth, but this purpose is still debated [3,6].”
BackgroundGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
Conversion of Thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects
Braverman, L. E., Ingbar, S. H., & Sterling, K. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106304 · Cited by 485 · cited 1×
“demonstrated that the peripheral amount of T3, which is the biologically active hormone, mainly results from the extrathyroidal conversion of T4 to T3 [9].”
BackgroundBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 2×
“However, a number of studies have shown that L-T4 monotherapy does not correct the whole symptomatology of hypothyroidism in 100% of patients, in that 5 -- 10% of them still complain of residual symptoms [10].”
BackgroundResult2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437 · cited 1×
“The combination of L-T4 plus liothyronine (L-T3) has yielded, nevertheless, contrasting results [10-14].”
ResultThyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · cited 3×
“The former include gastrointestinal diseases [17,23-25] and gastrointestinal modifications after bariatric surgery [26], the latter include beverages [27,28] and drugs [25].”
BackgroundConditions and drugs interfering with thyroxine absorption
Liwanpo, L., & Hershman, J. M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.06.006 · Cited by 222 · cited 2×
“, the proton pump inhibitors [PPIs] [25,29]), thus preventing the complete dissolution of tablet L-T4, or by binding L-T4 into insoluble complexes (e.”
BackgroundTiming of levothyroxine administration affects serum thyrotropin concentration
Bach-Huynh, T.-G., Nayak, B., Loh, J., Soldin, S., & Jonklaas, J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0860 · Cited by 198 · cited 1×
“Indeed, the maximum absorption occurs after the overnight fasting in the morning, whereas the lowest occurs when L-T4 is taken together with breakfast [19,22].”
BackgroundClyde, P. W., Harari, A. E., Getka, E. J., & Shakir, K. M. M. (2003) · JAMA · doi:10.1001/jama.290.22.2952 · Cited by 195 · cited 1×
“The combination of L-T4 plus liothyronine (L-T3) has yielded, nevertheless, contrasting results [10-14].”
ResultKENDALL, E. C. (1915) · Journal of the American Medical Association · doi:10.1001/jama.1915.02570510018005 · Cited by 192
Research works printed but not linked: 29
- Biondi B, 2014, Endocr Rev
- 10.1016/j.mcna.2012.01.002 · DOI
- 10.1016/j.biopha.2008.07.056 · DOI
- 10.1210/jc.2011-2735 · DOI · Paper page
- 10.1001/jama.1983.03340150087037 · DOI · Paper page
- 10.4061/2011/809341 · DOI
- 10.1210/jc.2004-2111 · DOI · Paper page
- 10.1111/j.1365-2036.2008.03889.x · DOI
- 10.2165/00003088-200443140-00006 · DOI
- Asik M, 2013, Endocrine
- 10.1111/j.1467-789X.2009.00614.x · DOI · Paper page
- 10.1201/b12117-31 · DOI
- 10.1016/j.ijcard.2008.06.022 · doi:10.1016/j.ijcard.2008.06.022
- 10.1172/JCI103659 · DOI · Paper page
- 10.1016/S0022-3476(97)70215-4 · DOI
- 10.1007/s11999-007-0099-x · doi:10.1007/s11999-007-0099-x
- 10.1097/01.pec.0000190240.81222.9a · DOI
- 10.1089/thy.2006.16.1047 · DOI
- 10.1097/MAJ.0b013e31817ee556 · DOI
- Torres MS, 2011, Irwin & Rippe’s intensive care medicine, 1055
- Benvenga S, 2012, Thyroid, 22, A50
- 10.1517/17425247.2012.701616 · DOI
- Santaguida M, 2013, Thyroid, 23, A53
- 10.1111/j.1360-0443.2009.02756.x · DOI
- 10.1055/s-0032-1329951 · DOI · Paper page
- 10.1111/j.1365-2885.2007.00935.x · DOI
- Brancato D, 2014, Endocr Pract
- Vita R, 2013, Thyroid, 23, A
- Le Couteur DG, 2004, Aust Fam Physician, 33, 777
Cited by
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.10.025 · Cited by 608
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0406 · Cited by 510
Mechanick, J. I., Apovian, C., Brethauer, S., Timothy Garvey, W., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah‐Pollack, R., Seger, J., et al. (2020) · Obesity · doi:10.1002/oby.22719 · Cited by 389
Gastrointestinal malabsorption of thyroxine
Virili, C., Antonelli, A., Santaguida, M. G., Benvenga, S., & Centanni, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00168 · Cited by 164
“Excipients have several functions, and the sa me excipient may serve more than one function (Table I) (16).”
BackgroundSelf-citationInositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
Self-citation
Metadata
- Authors
- Vita, R., Fallahi, P., Antonelli, A., & Benvenga, S.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2014-06-04
- Volume
- 11
- Issue
- 7
- Pages
- 1103-1111
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2104359662
- Cited by
- 93
- References
- 32
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The administration of l-thyroxine as soft gel capsule or liquid solution. https://app.cochat.ai/papers/10.1517/17425247.2014.918101
- The paper
- Vita, R., Fallahi, P., Antonelli, A., & Benvenga, S. (2014). The administration of l-thyroxine as soft gel capsule or liquid solution. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.2014.918101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.